

## Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drugs/drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee.

MO HealthNet Division’s clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD.

- All clinical information for consideration should be forwarded to Karen Powell, PharmD, MS at [Karen.Powell@gainwelltechnologies.com](mailto:Karen.Powell@gainwelltechnologies.com). These submissions should generally follow the AMCP guideline format.
- Financial evaluations for these therapeutic class reviews are conducted by Gainwell Technologies, LLC. Companies wishing to discuss opportunities for supplemental rebates and/or the policy surrounding the PDL process should contact [GWTContracting@gainwelltechnologies.com](mailto:GWTContracting@gainwelltechnologies.com) and Sandy Kapur, PharmD at [Sandy.Kapur@gainwelltechnologies.com](mailto:Sandy.Kapur@gainwelltechnologies.com).
- If a public presentation is desired, please contact Carmen Burton at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961.

The Drug PA Committee will convene at 10:00 a.m. on Tuesday, January 16, 2024.

### Therapeutic Class Name

Anti-infectives
<ul style="list-style-type: none"> <li>• Anti-retroviral Therapy (ART)</li> <li>• Cephalosporins, 1<sup>st</sup> Generation</li> <li>• Cephalosporins, 2<sup>nd</sup> Generation</li> <li>• Cephalosporins, 3<sup>rd</sup> Generation</li> <li>• Fluoroquinolones, Oral</li> <li>• Gastrointestinal Antibiotics</li> <li>• Macrolides</li> <li>• Penicillins</li> <li>• Tetracyclines</li> <li>• Vaginal Antibiotics</li> </ul>

### Central Nervous System

- Alzheimer's Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists and Combinations
- Analgesics, Fibromyalgia Agents
- Analgesics, Neuropathic Pain Agents
- Analgesics, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Analgesics, Opiate Emergency Reversal Agents
- Analgesics, Opioid and Select Alcohol Dependence Agents
- Analgesics, Opioids, Long-acting Narcotics
- Analgesics, Tramadol-like Agents
- Anti-migraine, Alternative Agents
- Anti-migraine, Serotonin (5-HT) Receptor Agonists
- Anti-Parkinsonism Agents, Monoamine Oxidase B Inhibitors
- Anti-Parkinsonism Agents, Non-ergot Dopamine Agonists
- Antipsychotics Atypical (2<sup>nd</sup> Generation) Oral and Transdermal Products
- Antipsychotics Atypical (2<sup>nd</sup> Generation) Depot Products
- Calcitonin Gene-related Peptide (CGRP) Receptors
- Sedative Hypnotics, Benzodiazepines
- Sedative Hypnotics, Non-benzodiazepines
- Sedative Hypnotics, Non-benzodiazepines, Melatonin Receptor Agonists
- Skeletal Muscle Relaxants
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors

### Dermatologic Agents

- Topical Antibiotics, Mupirocin

### Endocrine and Metabolic Agents

- Agents for Hypoglycemia
- Somatostatin Agents

### Gastrointestinal

- Agents for Opioid-induced Constipation, Opioid Antagonists
- Antiemetics, 5-HT<sub>3</sub> and NK<sub>1</sub> Injectable Agents
- Antiemetics, 5-HT<sub>3</sub>, NK<sub>1</sub> and Other Select Non-injectable Agents
- Irritable Bowel Syndrome (IBS)/Chronic Idiopathic Constipation (CIC) Agents
- IBS Agents, Anti-diarrheal

### Oral Oncology

- Anti-androgenic Agents
- Cyclin-dependent Kinase (CDK) 4/6 Inhibitors
- Mitogen-activated Extracellular Kinase 1/2 (MEK1/MEK2)–Protein Kinase B-raf (BRAF) Kinase Inhibitors
- Systemic Enzyme Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors
- Systemic Enzyme Inhibitors, Poly (ADP-ribose) Polymerase (PARP) Inhibitors

### Respiratory

- Agents to Treat Hereditary Angioedema